Capitalization 1.83TCr 1,53000Cr P/E ratio 2024 *
22.7x
P/E ratio 2025 * 21.5x
Enterprise value 1.71TCr 1,43000Cr EV / Sales 2024 *
4.59x
EV / Sales 2025 * 4.17x
Free-Float
77.04%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.14%
1 week+0.04%
Current month+5.71%
1 month+8.29%
3 months+1.68%
6 months+5.06%
Current year+9.85%
More quotes
1 week
77.41
Extreme 77.41
80.38
1 month
71.09
Extreme 71.085
80.38
Current year
70.53
Extreme 70.53
80.38
1 year
64.02
Extreme 64.02
82.45
3 years
59.78
Extreme 59.78
87.88
5 years
26.49
Extreme 26.49
87.88
10 years
22.70
Extreme 22.7
87.88
More quotes
Manager TitleAgeSince
Chief Executive Officer 60 07/13/07
Director of Finance/CFO 54 01/06/01
Public Communications Contact - 01/21/01
Director TitleAgeSince
Director/Board Member 70 22/07/22
Director/Board Member 53 01/11/01
Director/Board Member 74 06/13/06
More insiders

Other Advanced Medical Equipment & Technology

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+0.13%+0.04%-3.48%+8.56% 1.83TCr
+1.51%-0.14%-2.95%+4.21% 21TCr
+5.97%+5.73%+3.33%-8.48% 19TCr
-1.27%+4.02%+40.81%+39.98% 16TCr
+0.64%+0.83%+51.02%+78.57% 12TCr
-0.82%-1.93%+3.24%-3.47% 6.48TCr
-0.90%-0.31%-4.31%-20.05% 5.3TCr
-2.66%-0.32%-7.77%-38.81% 4.72TCr
-0.61%-2.52%+3.84%-12.92% 3.89TCr
-0.70%-2.42%+0.01% - 3.71TCr
Average +0.16%+0.69%+8.37%+5.29% 9.33TCr
Weighted average by Cap. +1.11%+1.26%+13.15%+12.76%
See all sector performances
Ratios2024 *2025 *
Net sales 403.06Cr 34TCr 424.93Cr 36TCr
Net income 82Cr 6.85TCr 86Cr 7.17TCr
Net Debt 22Cr 1.81TCr -57Cr -4.76TCr
More financial data * Estimated data
Logo Hologic, Inc.
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Employees
6,990
Calendar
Related indices
More about the company
Date Price Change Volume
23/24/23 78.49 $ +0.14% 289 810
22/24/22 78.38 $ +0.35% 601,500
19/24/19 78.11 $ +0.58% 1,660,498
18/24/18 77.66 $ -1.56% 2,332,247
17/24/17 78.89 $ +0.55% 2,177,366

Delayed Quote Nasdaq, July 23, 2024 at 10:21 pm IST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
78.38USD
Average target price
85.80USD
Spread / Average Target
+9.47%
Consensus